Dr. Reddy’s Advances Biosimilar Pipeline with FDA Review Acceptance for DRL_AB

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “D...

February 24, 2026 | Tuesday | News
Altesa BioSciences Raises $75 Million Series B Led by Forbion to Advance First-in-Class Rhinovirus Therapy Vapendavir into Phase 2b

  -Financing led by Forbion, joined by Sanofi and existing investors Medicxi, Pitango, and Atlantic Partners- -Proceeds to advance vapendavir, a fir...

February 23, 2026 | Monday | News
Stellaromics Launches Pyxa™, the First Commercial Platform for Multiplexed 3D Spatial Transcriptomics in Intact Tissue

Stellaromics launched Pyxa™, the first commercially available platform to deliver multiplexed 3D spatial transcriptomics in intact tissue up to 100...

February 23, 2026 | Monday | News
Sift Biosciences Raises $3.7M Pre-Seed Round to Advance AI-Driven Peptide Immunotherapy Platform

Pre-Seed Round Co-Led By Freeflow Ventures and Lifespan Vision Ventures With Participation From Valuence Ventures, Eisai Innovation, SBI US Gateway Fun...

February 20, 2026 | Friday | News
Rezon Bio Secures U.S. Food and Drug Administration Approval for Commercial Biosimilar Manufacturing at Warsaw-Duchnice Facility

Rezon Bio announces that its Warsaw-Duchnice facility has received approval from the U.S. Food and Drug Administration (FDA) for the commercial manufactu...

February 20, 2026 | Friday | News
Daiichi Sankyo and AstraZeneca Advance ENHERTU Toward EU Approval in Early Breast Cancer Following Landmark Phase 3 Risk Reduction Data

Based on DESTINY-Breast05 phase 3 trial results, which showed ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared to T-D...

February 20, 2026 | Friday | News
Primera Analytical Solutions Accelerates FDA-Compliant Digital Transformation with Cenevo’s Labguru Platform

Primera Analytical Solutions (Primera), an FDA-compliant analytical Contract Research Organization (CRO), has selected Cenevo’s  Labguru electro...

February 20, 2026 | Friday | News
Telix Advances Precision Neuro-Oncology Strategy with European Filing for TLX101-Px

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that it has submitted a marketing authorization application (M...

February 19, 2026 | Thursday | News
Bio Usawa and Nanoly Bioscience Partner to Revolutionize Biologic and Vaccine Distribution with DynaShield™

Bio Usawa, a leader in expanding global access to biopharmaceuticals, and Nanoly Bioscience, a pioneer in chemical stabilization,  announced a defin...

February 19, 2026 | Thursday | News
Andelyn Biosciences Expands Commitment to Rare Disease Community with NKH Gene Therapy Manufacturing Program

Andelyn Biosciences, Inc., a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has been selecte...

February 19, 2026 | Thursday | News
Sapu Bioscience Secures Global IP Fortress for OT-101, Advancing Integrated CNS Platform in Neurology and Oncology

Sapu Bioscience announced advancements in its global IP portfolio supporting OT-101, its proprietary TGF-β antisense therapeutic platform, stre...

February 18, 2026 | Wednesday | News
InnoCare Pharma Doses First Patient in Phase II/III Trial of Soficitinib for Chronic Spontaneous Urticaria

InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced &nb...

February 17, 2026 | Tuesday | News
QuidelOrtho Strengthens Global Immunoassay Portfolio Through Strategic Agreement With Lifotronic Technology

QuidelOrtho has entered a long-term strategic supply agreement with Lifotronic Technology Co., Ltd. (Lifotronic Technology Co., Ltd., stock code: 68838...

February 17, 2026 | Tuesday | News
Alto Neuroscience, Inc. Completes Patient Enrollment in Phase 2 Trial of ALTO-101 for Schizophrenia-Related Cognitive Impairment

-Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medi...

February 16, 2026 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close